AU2017246455B2 - Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders - Google Patents

Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders Download PDF

Info

Publication number
AU2017246455B2
AU2017246455B2 AU2017246455A AU2017246455A AU2017246455B2 AU 2017246455 B2 AU2017246455 B2 AU 2017246455B2 AU 2017246455 A AU2017246455 A AU 2017246455A AU 2017246455 A AU2017246455 A AU 2017246455A AU 2017246455 B2 AU2017246455 B2 AU 2017246455B2
Authority
AU
Australia
Prior art keywords
alkyl
cycloalkyl
membered
alkoxyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017246455A
Other languages
English (en)
Other versions
AU2017246455A1 (en
Inventor
Elyse Marie Josee Bourque
Andrew C. Good
Peter T. Lansbury
Renato T. Skerlj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial R&D Investments SA
Original Assignee
Bial R&D Investments SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial R&D Investments SA filed Critical Bial R&D Investments SA
Publication of AU2017246455A1 publication Critical patent/AU2017246455A1/en
Assigned to BIAL – BioTech Investments, Inc. reassignment BIAL – BioTech Investments, Inc. Request for Assignment Assignors: LYSOSOMAL THERAPEUTICS INC.
Application granted granted Critical
Publication of AU2017246455B2 publication Critical patent/AU2017246455B2/en
Assigned to BIAL - R&D INVESTMENTS, S.A. reassignment BIAL - R&D INVESTMENTS, S.A. Request for Assignment Assignors: BIAL – BioTech Investments, Inc.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017246455A 2016-04-06 2017-04-06 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders Ceased AU2017246455B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318929P 2016-04-06 2016-04-06
US62/318,929 2016-04-06
PCT/US2017/026280 WO2017176960A1 (en) 2016-04-06 2017-04-06 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders

Publications (2)

Publication Number Publication Date
AU2017246455A1 AU2017246455A1 (en) 2018-10-25
AU2017246455B2 true AU2017246455B2 (en) 2021-09-30

Family

ID=60001526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017246455A Ceased AU2017246455B2 (en) 2016-04-06 2017-04-06 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders

Country Status (12)

Country Link
US (4) US11192892B2 (OSRAM)
EP (1) EP3440080A4 (OSRAM)
JP (1) JP7038063B2 (OSRAM)
KR (2) KR20180133461A (OSRAM)
CN (1) CN109311887B (OSRAM)
AU (1) AU2017246455B2 (OSRAM)
BR (1) BR112018070586A8 (OSRAM)
CA (1) CA3020287A1 (OSRAM)
IL (1) IL262177B (OSRAM)
MX (1) MX2018012211A (OSRAM)
SG (1) SG11201808830YA (OSRAM)
WO (1) WO2017176960A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
PT3215511T (pt) 2014-11-06 2024-05-22 Bial R&D Invest S A Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440080A4 (en) 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
CN110698484B (zh) * 2019-06-05 2021-11-05 陕西理工大学 含吡唑并[1,5-a]嘧啶的衍生物、药用组合物及应用
CN115108972A (zh) * 2022-08-29 2022-09-27 北京迪泰医药科技有限公司 一种2-甲基-3-氟-5-溴吡啶的合成方法
WO2025014639A2 (en) * 2023-07-07 2025-01-16 The Johns Hopkins University Neutral sphingomyelinase inhibitors
WO2025146216A1 (zh) * 2024-01-05 2025-07-10 成都赜灵生物医药科技有限公司 六并五氮杂环酰胺类化合物及其用途
CN118184599A (zh) * 2024-02-29 2024-06-14 重庆药友制药有限责任公司 一种阿莫奈韦中间体的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048066A2 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
WO2012078855A1 (en) * 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
WO2015012328A1 (ja) * 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
WO2015073267A1 (en) * 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
JP3763997B2 (ja) 1999-05-13 2006-04-05 富士写真フイルム株式会社 感熱記録材料
JP4331823B2 (ja) 1999-05-21 2009-09-16 富士フイルム株式会社 ピロロ［１，２−ａ］−１，３，５−トリアジン−４−オン系化合物
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
JP4070966B2 (ja) 2001-06-28 2008-04-02 株式会社カネボウ化粧品 新規ガラクトシルセラミド類縁体及び用途
EP1440071B1 (en) 2001-10-22 2005-10-26 Pfizer Inc. Imidazopyridine compounds as 5-ht 4? receptor modulators
AU2003211424A1 (en) 2002-03-01 2003-09-16 Yamanouchi Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
US20050137223A1 (en) 2003-11-12 2005-06-23 Amicus Therapeutics, Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US7645756B2 (en) 2004-02-18 2010-01-12 Banyu Pharmaceutical Co. Ltd. Nitrogenous fused heteroaromatic ring derivative
US8318724B2 (en) 2004-05-14 2012-11-27 The Cleveland Clinic Foundation Small molecule inhibitors of MRP1 and other multidrug transporters
AU2005254657B2 (en) 2004-06-21 2011-03-17 F. Hoffmann-La Roche Ag Pyrrazolo-pyrimidine derivatives
JP2008508337A (ja) 2004-08-02 2008-03-21 シュバルツ ファルマ アクチェンゲゼルシャフト インドリジンカルボキサミド並びにそのアザ及びジアザ誘導体
DE102004049363A1 (de) 2004-10-08 2006-04-13 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
AU2006206573B9 (en) 2005-01-19 2011-09-29 Merck Sharp & Dohme Corp. Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2006212457B2 (en) * 2005-02-11 2011-04-14 F. Hoffmann-La Roche Ag Pyrazolo-pyrimidine derivatives as mGLuR2 antagonists
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
AU2006240769A1 (en) 2005-04-21 2006-11-02 Dainippon Sumitomo Pharma Co., Ltd. N-substituted phenylacetamide derivative and pharmaceutical composition comprising the same
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JP5102212B2 (ja) 2005-10-06 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
TWI372760B (en) * 2005-10-21 2012-09-21 Mitsubishi Tanabe Pharma Corp A pyrazolo[1,5-a]pyrimidine compound
RU2008127263A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) ПИРАЗОЛ [1,5-a] ПИРИДИН-3-КАРБОНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ EphB-И VEGFR2-КИНАЗЫ
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
KR101402554B1 (ko) 2006-06-23 2014-06-19 아미쿠스 세라퓨틱스, 인코포레이티드 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
WO2008019363A2 (en) 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5ht3 modulators
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US20080221092A1 (en) 2006-11-20 2008-09-11 Harald Bluhm Heterobicyclic metalloprotease inhibitors
US20080255153A1 (en) 2007-03-28 2008-10-16 Biovitrum Ab (Publ) New compounds
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
KR20100035635A (ko) 2007-06-21 2010-04-05 아이알엠 엘엘씨 단백질 키나제 억제제 및 그의 사용 방법
JP5479105B2 (ja) 2007-11-05 2014-04-23 国立大学法人佐賀大学 新規ユビキリン結合性小分子
US20110046127A1 (en) 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
JP2011504931A (ja) 2007-11-28 2011-02-17 シェーリング コーポレイション プロテインキナーゼ阻害剤としての２−フルオロピラゾロ［１，５−ａ］ピリミジン
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
WO2009119088A1 (ja) 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
CA2723135A1 (en) 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quenolines and related analogs as sirtuin modulators
JP5749169B2 (ja) 2008-10-14 2015-07-15 アストラゼネカ アクチボラグ 細菌感染の処置用の縮合スピロ環式ヘテロ芳香族化合物
JP5769199B2 (ja) 2008-10-31 2015-08-26 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物と方法
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US9085560B2 (en) 2009-08-17 2015-07-21 Intellikine, Inc. Heterocyclic compounds and uses thereof
MX340490B (es) 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
TW201217312A (en) 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9169260B2 (en) 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
CN103764166B (zh) 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
MX348548B (es) 2011-08-18 2017-06-19 Nippon Shinyaku Co Ltd Derivado heterociclico y farmaceutico.
MX348470B (es) 2011-09-02 2017-06-13 Bayer Ip Gmbh Pirimidinas anilladas sustituidas y uso de las mismas.
WO2013059119A1 (en) 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
BR112014009531A8 (pt) * 2011-10-20 2018-01-16 Glaxosmithkline Llc aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína
MX2014007731A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
WO2013134079A1 (en) 2012-03-05 2013-09-12 Amgen Inc. Oxazolidinone compounds and derivatives thereof
CA2866164C (en) 2012-03-09 2020-07-07 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
HK1199814A1 (en) 2012-03-09 2015-07-24 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
US9464035B2 (en) 2012-03-28 2016-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
MX2014014531A (es) 2012-05-31 2015-04-08 Hoffmann La Roche Derivados de aminoquinazolina y piridopirimidina.
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
WO2014025651A1 (en) 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
JP2015532650A (ja) 2012-09-05 2015-11-12 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 非生物的植物ストレスに対する活性物質としての置換された２−アミドベンズイミダゾール類、２−アミドベンゾオキサゾール類および２−アミドベンゾチアゾール類またはそれらの塩の使用
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
US9938258B2 (en) 2012-11-29 2018-04-10 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
SMT202000713T1 (it) 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
KR20140086002A (ko) 2012-12-28 2014-07-08 한미약품 주식회사 Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체
US9718816B2 (en) 2013-03-15 2017-08-01 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof
WO2015026574A1 (en) 2013-08-20 2015-02-26 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
AR097543A1 (es) 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015147639A1 (en) 2014-03-27 2015-10-01 Academisch Medisch Centrum N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
PT3215511T (pt) 2014-11-06 2024-05-22 Bial R&D Invest S A Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CN108290894A (zh) 2015-07-01 2018-07-17 西北大学 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途
EP3317265A4 (en) 2015-07-01 2019-04-17 Northwestern University SUBSTITUTED CHINAZOLIN COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
US20190092789A1 (en) 2015-09-04 2019-03-28 Lysosomal Therapeutics Inc. Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
ES2828733T3 (es) 2015-11-18 2021-05-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
EP3416967B1 (en) 2016-02-18 2022-02-09 F. Hoffmann-La Roche AG Therapeutic compounds, compositions and methods of use thereof
EP3440080A4 (en) 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3452045A1 (en) 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
EP3452480A4 (en) 2016-05-05 2019-11-06 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
WO2019126776A1 (en) 2017-12-21 2019-06-27 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048066A2 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
WO2012078855A1 (en) * 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
WO2015012328A1 (ja) * 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
WO2015073267A1 (en) * 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AHMETAJ, S. et al., "Parallel synthesis of7-heteroaryl-pyrazolo[1,5-a]pyrimidine-3- carboxamides", Molecular Diversity, (2013-01-01), vol. 17, no. 4, doi:10.1007/s11030-013-9469-3, ISSN 1381-1991, pages 731 - 743 *
CAS Registry Number 1022459-94-4 ; STN Entry Date 25 May 2008; 5-(2-furanyl)-N-[(4-methylphenyl)methyl]-7-(trifluoromethyl)- pyrazolo[1,5-a]pyrimidine-3-carboxamide *
CAS Registry Number 1090443-11-0 ; STN Entry Date 26 December 2008; N-(dicyclopropylmethyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide *
CAS Registry Number 1099976-59-6; STN Entry Date 3 February 2009; N-(1-cyclopropyl-4-piperidinyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide *
CAS Registry Number 1224940-28-6; STN Entry Date 24 May 2010; N-cyclohexyl-5-methoxy-pyrazolo[1,5-a]pyrimidine-3-carboxamide *
CAS Registry Number 1224940-60-6; STN Entry Date 24 May 2010; N-cyclohexyl-5-(ethylamino)-pyrazolo[1,5-a]pyrimidine-3-carboxamide *
CAS Registry Number 1355610-51-3; STN Entry Date 7 February 2012; (2-Cyclopentyl-1-pyrrolidinyl)(5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methanone *
CAS Registry Number 1355851-51-2; STN Entry Date 8 February 2012; (2-Cyclohexyl-1-pyrrolidinyl)pyrazolo[1,5-a]pyrimidin-3-ylmethanone *
CAS Registry Number 1424084-03-6; STN Entry Date 15 March 2013; (4-bicyclo[2.2.1]hept-2-yl-1-piperazinyl)(2-methylpyrazolo[1,5-a]pyrimidin-3-yl)methanone *
CAS Registry Number 1624709-79-0; STN Entry Date 23 September 2014; 4-cyclopentyl-1-piperazinyl)(2-methylpyrazolo[1,5-a]pyrimidin-3-yl)methanone *
CAS Registry Number 696640-82-1; STN Entry Date 21 June 2004; 7-(difluoromethyl)-5-(4-methoxyphenyl)-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide *
CAS Registry Number 895779-11-0; STN Entry Date 25 July 2006; 5-(4-bromophenyl)-N-[(4-methoxyphenyl)methyl]-7-(trifluoromethyl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide *

Also Published As

Publication number Publication date
CN109311887A (zh) 2019-02-05
KR20230104752A9 (ko) 2024-11-15
MX2018012211A (es) 2019-03-28
US20200017507A1 (en) 2020-01-16
RU2018138688A (ru) 2020-05-19
JP7038063B2 (ja) 2022-03-17
CN109311887B (zh) 2022-09-13
CA3020287A1 (en) 2017-10-12
SG11201808830YA (en) 2018-11-29
KR20230104752A (ko) 2023-07-10
IL262177B (en) 2022-06-01
US20170349598A1 (en) 2017-12-07
AU2017246455A1 (en) 2018-10-25
BR112018070586A2 (pt) 2019-02-05
EP3440080A1 (en) 2019-02-13
US20230098494A1 (en) 2023-03-30
US10934298B2 (en) 2021-03-02
US11192892B2 (en) 2021-12-07
KR20180133461A (ko) 2018-12-14
BR112018070586A8 (pt) 2023-03-14
US20190330213A1 (en) 2019-10-31
RU2018138688A3 (OSRAM) 2020-08-31
JP2019510790A (ja) 2019-04-18
IL262177A (en) 2018-11-29
US12116369B2 (en) 2024-10-15
WO2017176960A1 (en) 2017-10-12
US9840510B1 (en) 2017-12-12
EP3440080A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
AU2017246455B2 (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2019416589B2 (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
AU2018221812B2 (en) Pyrrolo [1,2-b] pyridazine derivatives
AU2017261291C1 (en) Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
KR101548443B1 (ko) 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
TWI503319B (zh) 吡啶酮和氮雜吡啶酮之化合物及其使用方法
EP1383768B1 (en) Imidazo-pyrimidine derivatives as ligands for gaba receptors
JP6139690B2 (ja) ブルートンチロシンキナーゼの阻害剤
AU2020348675B2 (en) Azole-fused pyridazin-3(2H)-one derivatives
CN108699077A (zh) 作为rsv抑制剂的杂环化合物
JP2019510790A5 (OSRAM)
JP7046827B2 (ja) イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
EP2763990A1 (en) Pyrrolopyrazine kinase inhibitors
AU2010292487A1 (en) Heterocyclic compounds as janus kinase inhibitors
AU2004290643A1 (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with PDE-5 inhibiting activity
AU2009274027A1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2018066718A1 (en) Therapeutic compounds
CA3151232A1 (en) Pharmaceutical compounds
MX2013008629A (es) Inhibidores de histona desacetilasa y composiciones y metodos para su uso.
RU2799332C2 (ru) Пиразоло[1,5-a]пиримидинилкарбоксамиды и их применение для лечения патологических состояний
RU2773333C2 (ru) ЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ, ЗАМЕЩЕННЫЕ ИМИДАЗО[1,5-b]ПИРИДАЗИНЫ, РОДСТВЕННЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ
TW201706268A (zh) 羥基嘌呤類化合物及其應用
BR112014010459B1 (pt) Compostos e composição farmacêutica
NZ624021A (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BIAL - BIOTECH INVESTMENTS, INC.

Free format text: FORMER APPLICANT(S): LYSOSOMAL THERAPEUTICS INC.

PC1 Assignment before grant (sect. 113)

Owner name: BIAL - R&D INVESTMENTS, S.A.

Free format text: FORMER APPLICANT(S): BIAL - BIOTECH INVESTMENTS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired